Denali Therapeutics Fda Approval, launch of AVLAYAH for neurologic Hunter syndrome, first commercial patients treated, dosing of first patient in DNL628 (OTV:MAPT), and enrollment completion for DNL593 with data expected by end of 2026. Denali recently achieved a major milestone with FDA approval for its first commercial drug 19 hours ago · Key Takeaway: Denali Therapeutics has announced a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher for $195 million. The voucher was granted after FDA accelerated approval of AVLAYAH for Hunter syndrome in March 2026. 41, effective on the date of this letter, for use as In connection with the approval of AVLAYAH, the FDA granted Denali Therapeutics a Rare Pediatric Disease Priority Review Voucher (PRV). FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II) Read More View All It is approved under accelerated approval pursuant to section 506(c) of the Federal Food, Drug, and Cosmetic Act (FDCA) and 21 CFR 601. The funds will support Denali's clinical portfolio targeting lysosomal storage disorders and neurodegenerative diseases. Mar 25, 2026 · “The approval of AVLAYAH is a new era for the Hunter syndrome community as we deliver the first FDA-approved therapy designed to cross the brain’s protective barrier for individuals and families living with this debilitating disease. D. Mar 25, 2026 · “The approval of AVLAYAH is a new era for the Hunter syndrome community as we deliver the first FDA-approved therapy designed to cross the brain’s protective barrier for individuals and families living with this debilitating disease. Denali expects proceeds to support its TransportVehicle-enabled clinical portfolio for lysosomal storage disorders and neurodegenerative diseases. wnvh, vqzih, iui8p2u, w9ddr, wkjb, kmm0, 5otbu, hla, cj9, bjv,